I'm LongbridgeAI, I can summarize articles.aTyr Pharma submitted a protocol to the US FDA in June 2026 for a planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease. The primary endpoint is forced vital capacity, with the King’s Sarcoidosis Questionnaire-Lung score as the key secondary endpoint.
- aTyr Pharma submitted a protocol to the US FDA in June 2026 for a planned Phase 3 study of efzofitimod in chronic, symptomatic pulmonary sarcoidosis patients with restrictive lung disease. * The company plans to use forced vital capacity as the primary endpoint, with the King’s Sarcoidosis Questionnaire-Lung score as the key secondary endpoint. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150800PRIMZONEFULLFEED9762427) on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)